Aaron Cameron
Vermögen: - $ am 30.06.2026
Vermögen: - $ am 30.06.2026
Aaron Cameron is currently Chief Operating Officer at GH Research Plc since 2024.
Formerly, Mr. Cameron was Vice President-Supply Chain & Logistics at Iterum Therapeutics Plc from 2016 to 2021 and Head-Device Program Management at Viatris, Inc. from 2020 to 2021.
Education includes an MBA from the University of Bradford, graduate studies at the Royal College of Surgeons, and undergraduate studies at Dublin City University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GH RESEARCH PLC -.--% | 18.03.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| GH RESEARCH PLC | Geschäftsführer | 01.01.2024 |
| Unternehmen | Position | Ende |
|---|---|---|
| VIATRIS INC. | Corporate Officer/Principal | 01.01.2021 |
| ITERUM THERAPEUTICS PLC | Corporate Officer/Principal | 01.01.2021 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
University of Bradford
University of Bradford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Royal College of Surgeons
Royal College of Surgeons Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dublin City University
Dublin City University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Iterum Therapeutics Plc
Iterum Therapeutics Plc Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem | Health Technology |
Viatris, Inc.
Viatris, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Health Technology |
GH Research Plc
GH Research Plc Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel therapies for the management of psychiatric and neurological disorders | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen